[go: up one dir, main page]

PL3536380T3 - Szybko działające kompozycje insuliny - Google Patents

Szybko działające kompozycje insuliny

Info

Publication number
PL3536380T3
PL3536380T3 PL19161129T PL19161129T PL3536380T3 PL 3536380 T3 PL3536380 T3 PL 3536380T3 PL 19161129 T PL19161129 T PL 19161129T PL 19161129 T PL19161129 T PL 19161129T PL 3536380 T3 PL3536380 T3 PL 3536380T3
Authority
PL
Poland
Prior art keywords
acting insulin
fast acting
insulin compositions
compositions
fast
Prior art date
Application number
PL19161129T
Other languages
English (en)
Inventor
Michael Edward CHRISTE
Thomas Andrew HARDY
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3536380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3536380T3 publication Critical patent/PL3536380T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL19161129T 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny PL3536380T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
EP19161129.2A EP3536380B8 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions
PCT/US2015/029010 WO2015171484A1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions
EP15723388.3A EP3140008B1 (en) 2014-05-08 2015-05-04 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
PL3536380T3 true PL3536380T3 (pl) 2021-12-27

Family

ID=53189204

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15723388T PL3140008T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny
PL19161129T PL3536380T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15723388T PL3140008T3 (pl) 2014-05-08 2015-05-04 Szybko działające kompozycje insuliny

Country Status (36)

Country Link
US (2) US9439952B2 (pl)
EP (3) EP3536380B8 (pl)
JP (1) JP6050902B2 (pl)
KR (1) KR101858890B1 (pl)
CN (1) CN106456717B (pl)
AP (1) AP2016009525A0 (pl)
AR (1) AR100155A1 (pl)
AU (1) AU2015256355B2 (pl)
BR (1) BR112016024357B1 (pl)
CA (1) CA2945188C (pl)
CL (1) CL2016002772A1 (pl)
CY (2) CY1121669T1 (pl)
DK (2) DK3536380T3 (pl)
EA (1) EA031134B1 (pl)
ES (2) ES2891983T3 (pl)
HR (2) HRP20190777T1 (pl)
HU (2) HUE055742T2 (pl)
IL (1) IL248350B (pl)
JO (1) JO3624B1 (pl)
LT (2) LT3140008T (pl)
MA (1) MA39441A1 (pl)
ME (1) ME03384B (pl)
MX (1) MX367521B (pl)
NZ (1) NZ724919A (pl)
PE (1) PE20161408A1 (pl)
PH (1) PH12016502195B1 (pl)
PL (2) PL3140008T3 (pl)
PT (2) PT3536380T (pl)
RS (2) RS58726B1 (pl)
SG (1) SG11201608424WA (pl)
SI (2) SI3140008T1 (pl)
TN (1) TN2016000443A1 (pl)
TR (1) TR201906843T4 (pl)
TW (1) TWI685348B (pl)
UA (1) UA124919C2 (pl)
WO (1) WO2015171484A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー/エス プロテアーゼ安定化アシル化インスリンアナログ
EP3332810B1 (fr) 2012-11-13 2021-01-13 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
WO2017015760A1 (en) * 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN114904100A (zh) * 2016-01-29 2022-08-16 曼金德公司 干粉吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
KR102541885B1 (ko) 2016-09-26 2023-06-12 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드럭
ES2954180T3 (es) 2016-09-29 2023-11-20 Arecor Ltd Formulación farmacéutica que comprende un compuesto de insulina
WO2018109162A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
JOP20190277B1 (ar) * 2017-06-01 2023-09-17 Lilly Co Eli تركيبات إنسولين سريعة المفعول
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
IL277720B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
EP3773472A1 (en) 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
IL280891B1 (en) 2018-09-18 2025-09-01 Lilly Co Eli Treprostinil erbumine salt
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
JP7518149B2 (ja) * 2019-07-12 2024-07-17 ノヴォ ノルディスク アー/エス 高濃度インスリン製剤
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP7608480B2 (ja) 2020-06-09 2025-01-06 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
KR102849520B1 (ko) 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
CA3209987A1 (en) 2021-03-03 2022-09-09 Hitesh Batra A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
EP4516297A1 (en) * 2022-04-29 2025-03-05 Zhaoke Pharmaceutical (Guangzhou) Co., Ltd Treprostinil soft mist inhalant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Glp−1および基礎インスリンの予備混合物
AU2003236201A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US7879909B2 (en) * 2004-04-12 2011-02-01 United Therapeutics Corporation Use of Treprostinil to treat neuropathic diabetic foot ulcers
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
JP2012503668A (ja) * 2008-09-25 2012-02-09 アラダイム コーポレーション 肺深部へのトレプロスチニルの肺送達
MX2011012764A (es) * 2009-06-26 2012-01-20 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
TWI513462B (zh) * 2009-11-13 2015-12-21 Toray Industries 糖尿病之治療或預防藥
MX2013006174A (es) 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
IN2014CN00989A (pl) * 2011-08-12 2015-04-10 Ascendis Pharma As
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2015031709A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
JO3624B1 (ar) 2020-08-27
ES2733639T3 (es) 2019-12-02
TR201906843T4 (tr) 2019-05-21
JP2016523807A (ja) 2016-08-12
US20160129087A1 (en) 2016-05-12
EA031134B1 (ru) 2018-11-30
US10172922B2 (en) 2019-01-08
PL3140008T3 (pl) 2019-09-30
EP3943155A1 (en) 2022-01-26
CY1121669T1 (el) 2020-07-31
PT3536380T (pt) 2021-09-02
KR20160133567A (ko) 2016-11-22
TW201625291A (zh) 2016-07-16
HRP20211415T1 (hr) 2021-12-10
AP2016009525A0 (en) 2016-10-31
CL2016002772A1 (es) 2017-06-09
TWI685348B (zh) 2020-02-21
MX367521B (es) 2019-08-26
PE20161408A1 (es) 2016-12-28
EA201691911A1 (ru) 2017-02-28
CA2945188A1 (en) 2015-11-12
MA39441A1 (fr) 2017-06-30
ME03384B (me) 2020-01-20
BR112016024357B1 (pt) 2022-08-23
EP3140008A1 (en) 2017-03-15
CA2945188C (en) 2018-12-11
AU2015256355A1 (en) 2016-10-27
JP6050902B2 (ja) 2016-12-21
EP3536380B8 (en) 2021-09-22
AU2015256355B2 (en) 2017-09-14
CY1124454T1 (el) 2022-07-22
PH12016502195A1 (en) 2017-02-06
EP3140008B1 (en) 2019-04-17
US20160367640A1 (en) 2016-12-22
EP3536380A1 (en) 2019-09-11
EP3536380B1 (en) 2021-07-07
HRP20190777T1 (hr) 2019-08-23
CN106456717A (zh) 2017-02-22
SI3536380T1 (sl) 2021-09-30
LT3140008T (lt) 2019-05-27
US9439952B2 (en) 2016-09-13
IL248350B (en) 2020-03-31
UA124919C2 (uk) 2021-12-15
MX2016014643A (es) 2017-03-06
SG11201608424WA (en) 2016-11-29
RS62291B1 (sr) 2021-09-30
CN106456717B (zh) 2020-01-17
TN2016000443A1 (en) 2018-04-04
BR112016024357A2 (pt) 2017-10-10
HUE055742T2 (hu) 2021-12-28
DK3536380T3 (da) 2021-08-02
NZ724919A (en) 2018-01-26
PH12016502195B1 (en) 2017-02-06
KR101858890B1 (ko) 2018-05-16
DK3140008T3 (da) 2019-06-24
ES2891983T3 (es) 2022-02-01
WO2015171484A1 (en) 2015-11-12
SI3140008T1 (sl) 2019-06-28
IL248350A0 (en) 2016-11-30
PT3140008T (pt) 2019-06-25
RS58726B1 (sr) 2019-06-28
AR100155A1 (es) 2016-09-14
HUE044370T2 (hu) 2019-10-28
LT3536380T (lt) 2021-08-10

Similar Documents

Publication Publication Date Title
DK3140008T3 (da) Hurtigtvirkende insulinsammensætninger
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3233108T3 (da) Hurtigtvirkende insulinsammensætninger
BR112016030368A2 (pt) composição oftálmica
DK3542812T3 (da) Glycopeptidsammensætninger
SMT202400518T1 (it) Composizioni anticancro
DK3198111T3 (da) Forbedret prop
FR3024363B1 (fr) Composition thermogelifiable
LT3226842T (lt) Priešvėžinės kompozicijos
LT3226843T (lt) Priešvėžinės kompozicijos
DK3171700T3 (da) Infusionsanlæg
DK3129007T3 (da) Vaccinesammensætninger
CL2017000639A1 (es) Composición
DK3331498T3 (da) Nasalsammensætning
HUE070090T2 (hu) Összetétel
DK3200827T3 (da) Sammensætninger
DK3148513T3 (da) Ceritinib-formulering
DK3217964T3 (da) Sammensætning
DK3193856T3 (da) Formulering
DK3089740T3 (da) Farmaceutisk sammensætning
FR3019552B1 (fr) Composition filmogene
DK3001076T3 (da) Tilbageløbsforhindrer
DK3160441T3 (da) Flydende thioureylensammensætninger
DK3119380T3 (da) Sammensætning omfattende biprodukter
UA28875S (uk) Шприц